Anuh Pharma Ltd
Anuh Pharma Q4 FY25: Revenue ₹198.14 Cr, PAT ₹12.46 Cr
Q4 FY25 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹198Cr
- +20.7% YoY
- Net profit
- ₹12Cr
- −20% YoY
- Margin
- 9%
- −3 pp YoY
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Based on Anuh Pharma Ltd's Q4 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue difference). EBITDA for the quarter ended 31/03/2025: ₹20.07 Cr, a 27.61% increase QoQ; margin: 10.13%.
From Anuh Pharma Ltd's Q4 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue difference).
- Quarterly revenue grew 24.22% quarter-on-quarter, from ₹159.51 crore in Q3 FY 2025.
- The company reported its highest-ever quarterly revenue of ₹199.54 crore in Q4 FY 2025.
- Customer base increased from 698 to 737 in FY25; export customers grew from 260 to 304.
2 more points from Anuh Pharma Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Anuh Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Manufacturing capacity expanded from 1,800 MT to 2,200 MT in FY25 to strengthen portfolio and market presence.
- Planned expansion of Intermediate manufacturing capacity by 300 MTPA in FY26 aimed at improving efficiency and supporting new product launches.
- Expect to add 5 to 6 new API products in FY26 to contribute to revenue growth and business expansion.
- Infrastructure includes Zero Liquid Discharge Effluent Control system (treating 100% pollution), green belt for carbon footprint reduction, and 100% power backup via dedicated power line—indicative of ongoing facility enhancement but without disclosed investment figures.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Anuh Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Anuh Pharma Ltd said on order book & pipeline — free account, 30 seconds.
Anuh Pharma Ltd — Quarterly revenue & net profit
Anuh Pharma Ltd Q4 FY25 results — key figures
| ₹ Cr | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 198 | 164 | +20.7% | 160 | +23.8% |
| Operating profit (EBITDA) | 19 | 19 | 0% | 15 | +26.7% |
| Operating margin | 9% | 12% | -3 pp | 9% | 0 pp |
| Profit before tax | 17 | 20 | -15% | 13 | +30.8% |
| Net profit (PAT) | 12 | 15 | -20% | 10 | +20% |
| EPS (₹) | 1.24 | 1.53 | -19% | 1.03 | +20.4% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹185 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Anuh Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Jubilant Pharmo (Q4 FY25)
Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…
- Themis Medicare (Q4 FY25)
71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Lincoln Pharmaceuticals (Q4 FY25)
Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…
- Kopran (Q4 FY25)
1,372 Lakhs (~7.37% decline) . Key concall takeaways from Kopran Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Anuh Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Anuh Pharma Ltd Q4 FY25 results?
For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue difference). EBITDA for the quarter ended 31/03/2025: ₹20.07 Cr, a 27.61% increase QoQ; margin: 10.13%.
What is Anuh Pharma Ltd share price analysis?
Anuh Pharma Ltd currently shows a neutral. The stock trades at a P/E of 21.2 with a market cap of ₹937 Cr. Investors should review the full earnings analysis for detailed insights.
Is Anuh Pharma Ltd planning capital expenditure?
Manufacturing capacity expanded from 1,800 MT to 2,200 MT in FY25 to strengthen portfolio and market presence.
Keep Anuh Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.